The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China

Li, Jian; Zhao, Qiquan; Zhang, Shujun; Huang, Wenxiang; Xiong, Yujiao; Zhou, Xiangyang; Jia, Bin

doi:10.1007/s00705-013-1828-y

Cited by 9 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HAdV-C2 global seroprevalence is relatively high (36-92%) and ≥ HAdV-C5 [120,121]. HAdV-C6 was presented as a low prevalence type by one study in the United States (8.5% adult and 2% children [122] and reach 12% in of healthy adult in China [123]), while others studies show a seroprevalence rate fluctuating between 78% in Thailand and Cameroon; 73% in South Africa and 71% in Malawi [124].…”

Section: Moving Forwardmentioning

confidence: 96%

A review of 65 years of human adenovirus seroprevalence

Mennechet

Paris

Ouoba

et al. 2019

Expert Review of Vaccines

137

135

View full text Add to dashboard Cite

Introduction: Human adenovirus (HAdV)-derived vectors have been used in numerous pre-clinical and clinical trials during the last 40 years. Current research in HAdV-based vaccines focuses on improving transgene immunogenicity and safety. Because pre-existing humoral immunity against HAdV types correlate with reduced vaccine efficacy and safety, many groups are exploring the development of HAdV types vectors with lower seroprevalence. However, global seroepidemiological data are incomplete. Areas covered: The goal of this review is to centralize 65 years of research on (primarily) HAdV epidemiology. After briefly addressing adenovirus biology, we chronical HAdV seroprevalence studies and highlight major milestones. Finally, we analyze data from about 50 studies with respect to HAdVs types that are currently used in the clinic, or are in the developmental pipeline. Expert opinion: Vaccination is among the most efficient tools to prevent infectious disease. HAdVbased vaccines have undeniable potential, but optimization is needed and antivector immunity remains a challenge if the same vectors are to be administrated to different populations. Here, we identify gaps in our knowledge and the need for updated worldwide epidemiological data.

show abstract

Section: Moving Forwardmentioning

confidence: 96%

A review of 65 years of human adenovirus seroprevalence

Mennechet

Paris

Ouoba

et al. 2019

Expert Review of Vaccines

137

135

View full text Add to dashboard Cite

show abstract

“…The frequency of nAbs against ChAd6 are similar in these populations except in Africa where it peaks below 40%. 14,46,62 Furthermore, unlike rare human Ad serotypes, ChAd have demonstrated great efficacy in pre-clinical studies including ChAd7 in a mouse model of EBOV infection, 63 ChAd68 (SAd-24) in a NHP model of rabies, 64,65 ChAd63, ChAd7 or ChAd9 in combination with modified vaccinia Ankara (MVA) boost in a malaria mouse model, 66,67 and ChAdOx1 in a rodent model of Rift Valley Fever (RVF). 68 In addition, in Phase I clinical trials against Malaria and HCV, ChAd63 46 and ChAd3, 69 respectively, were found to be safe and able to generate robust, broad and polyfunctional T cell responses against the transgene.…”

Section: Ad Vectors Based On Alternative Adenovirusesmentioning

confidence: 99%

Pre-existing immunity against Ad vectors

Fausther-Bovendo

Kobinger

2014

Human Vaccines & Immunotherapeutics

216

104

View full text Add to dashboard Cite

Pre-existing immunity against human adenovirus (HAd) serotype 5 derived vector in the human population is widespread, thus hampering its clinical use. Various components of the immune system, including neutralizing antibodies (nAbs), Ad specific T cells and type I IFN activated NK cells, contribute to dampening the efficacy of Ad vectors in individuals with pre-existing Ad immunity. In order to circumvent pre-existing immunity to adenovirus, numerous strategies, such as developing alternative Ad serotypes, varying immunization routes and utilizing prime-boost regimens, are under pre-clinical or clinical phases of development. However, these strategies mainly focus on one arm of pre-existing immunity. Selection of alternative serotypes has been largely driven by the absence in the human population of nAbs against them with little attention paid to cross-reactive Ad specific T cells. Conversely, varying the route of immunization appears to mainly rely on avoiding Ad specific tissue-resident T cells. Finally, prime-boost regimens do not actually circumvent pre-existing immunity but instead generate immune responses of sufficient magnitude to confer protection despite pre-existing immunity. Combining the above strategies and thus taking into account all components regulating pre-existing Ad immunity will help further improve the development of Ad vectors for animal and human use.

show abstract

“…The majority of these adenovirus vectors are from species B, C, D, and E. Adenovirus vectors from avian, bovine, and other species have also been constructed, but their different genomic structures may necessitate the development of a novel manufacturing platform for clinical development (17,18). Old World monkey adenoviruses have been hypothesized to be distinct from both human and chimpanzee adenoviruses and may offer unique advantages, such as the ability to more efficiently bypass preexisting immunity to human adenoviruses (12,(19)(20)(21)(22)(23)(24), while maintaining the genomic structure and growth properties of human adenoviruses.…”

mentioning

confidence: 99%

Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors

Abbink

Maxfield

Ng’ang’a

et al. 2015

J Virol

View full text Add to dashboard Cite

Adenovirus vectors are widely used as vaccine candidates for a variety of pathogens, including HIV-1. To date, human and chimpanzee adenoviruses have been explored in detail as vaccine vectors. The phylogeny of human and chimpanzee adenoviruses is overlapping, and preexisting humoral and cellular immunity to both are exhibited in human populations worldwide. More distantly related adenoviruses may therefore offer advantages as vaccine vectors. Here we describe the primary isolation and vectorization of three novel adenoviruses from rhesus monkeys. The seroprevalence of these novel rhesus monkey adenovirus vectors was extremely low in sub-Saharan Africa human populations, and these vectors proved to have immunogenicity comparable to that of human and chimpanzee adenovirus vaccine vectors in mice. These rhesus monkey adenoviruses phylogenetically clustered with the poorly described adenovirus species G and robustly stimulated innate immune responses. These novel adenoviruses represent a new class of candidate vaccine vectors. IMPORTANCEAlthough there have been substantial efforts in the development of vaccine vectors from human and chimpanzee adenoviruses, far less is known about rhesus monkey adenoviruses. In this report, we describe the isolation and vectorization of three novel rhesus monkey adenoviruses. These vectors exhibit virologic and immunologic characteristics that make them attractive as potential candidate vaccine vectors for both HIV-1 and other pathogens. R ecombinant adenoviruses (Ads) are currently being explored as candidate vaccine vectors for multiple pathogens (1-6), as a result of their safety profile, manufacturability, and ability to induce broad and strong immune responses (7-16). Multiple human and chimpanzee adenovirus vectors have been developed to date (8,9,(11)(12)(13). The majority of these adenovirus vectors are from species B, C, D, and E. Adenovirus vectors from avian, bovine, and other species have also been constructed, but their different genomic structures may necessitate the development of a novel manufacturing platform for clinical development (17, 18). Old World monkey adenoviruses have been hypothesized to be distinct from both human and chimpanzee adenoviruses and may offer unique advantages, such as the ability to more efficiently bypass preexisting immunity to human adenoviruses (12,(19)(20)(21)(22)(23)(24), while maintaining the genomic structure and growth properties of human adenoviruses.We isolated simian adenoviruses from fecal samples from rhesus monkeys (Macaca mulatta) that were positive for adenoviruses by metagenomics sequencing (25). We performed whole-genome sequencing of these novel adenoviruses and determined their phylogeny in comparison with that of other human and simian adenoviruses. The basic genetic structure of these novel rhesus monkey adenoviruses proved similar to that of human adenoviruses (7,16,26). We vectorized three rhesus monkey adenoviruses and then assessed humans in sub-Saharan Africa for seroprevalence of these adenoviruses and ...

show abstract

The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China

Cited by 9 publications

References 32 publications

A review of 65 years of human adenovirus seroprevalence

A review of 65 years of human adenovirus seroprevalence

Pre-existing immunity against Ad vectors

Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors

Contact Info

Product

Resources

About